Organon (OGN) Liabilities and Shareholders Equity (2020 - 2026)

Organon has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $13.2 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $13.2 billion, down 2.39% year-over-year; the trailing twelve-month figure through Jun 2026 was $52.6 billion (changed 0.16% YoY), and the FY2025 annual result was $12.9 billion, down 1.79% from the prior year.
• Liabilities and Shareholders Equity rose to $13.2 billion in Q2 2026, from $13.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $13.6 billion in Q3 2025 and troughed at $10.4 billion in Q3 2022.
• A 5-year average of $12.0 billion and a median of $12.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity decreased 7.92%; it then increased 15.8% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $11.0 billion in 2022, then increased by 10.07% to $12.1 billion in 2023, then climbed by 8.65% to $13.1 billion in 2024, then fell by 1.79% to $12.9 billion in 2025, then climbed by 2.42% to $13.2 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $13.2 billion in Q2 2026, $13.0 billion in Q1 2026, and $12.9 billion in Q4 2025.